Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCo-Diagnostics, Inc. Common Stock

Co-Diagnostics, Inc. Common Stock

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.2709 USD 0.01 ( 5.49%)
Last update at 2026-11-09T15:45:00Z
VOLUME
360867
Market Cap
7.96M

Momentum Score

…

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.26
Low
0.28
High
52 Week Price Range
0.94
Low
46.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Co-Diagnostics, Inc. develops PCR-based molecular diagnostic tests and licenses its CoPrimer assay chemistry for infectious disease detection. Long-term growth may be driven by CoPrimer licensing and kit sales, expansion beyond COVID-19, and international distribution that could support recurring reagent revenue.
Key risks include a concentrated product mix and waning pandemic-driven demand, intense competition from larger diagnostics companies, regulatory and reimbursement uncertainty, and historical operating losses that may require further financing.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.26
Dividend Yield
-
Revenue TTM
0.72M
Revenue Per Share
0.30
Gross Profit TTM
0.31M
Debt / Equity
0.06
ROE
-174.77%
Net Debt
-10.65M
ROCE
-147.54%
Diluted EPS TTM
-25.89

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -48.51M -37.58M -38.11M -18.85M 45.64M
Net income -46.90M -37.64M -35.33M -14.24M 36.66M
Selling general administrative 9.06M 16.16M 14.28M 14.26M 11.55M
Selling and marketing expenses 2.38M 4.48M 6.86M 7.34M 13.40M
Gross profit -0.91M 2.92M 2.63M 28.74M 86.31M
Reconciled depreciation 1.11M 1.38M 1.22M 1.28M 0.34M
Ebit -31.28M -40.08M -42.71M -11.59M 46.06M
Ebitda -30.18M -38.70M -41.48M -2.68M 46.44M
Depreciation and amortization 1.11M 1.38M 1.23M 8.91M 0.38M
Non operating income net other - - - 8.13M -0.43M
Operating income -31.49M -40.08M -42.71M -11.59M 46.06M
Other operating expenses 31.91M 44.00M 49.52M 45.81M 51.82M
Interest expense - - - 14.88M 0.47M
Tax provision -1.62M 0.06M -9.75M -4.61M 8.98M
Interest income 0.29M 1.09M 1.05M 0.70M 0.05M
Net interest income 0.29M 1.09M 1.05M 0.70M 0.05M
Non recurring - - - 15.39M -
Income tax expense -1.62M 0.06M -2.78M -4.61M 8.98M
Total revenue 0.42M 3.92M 6.81M 34.22M 97.89M
Total operating expenses 30.58M 43.00M 45.33M 40.33M 40.25M
Cost of revenue 1.33M 1.00M 4.18M 5.48M 11.57M
Total other income expense net -17.02M 2.50M 4.60M -7.26M -0.43M
Net income from continuing ops -46.90M -37.64M -42.56M -14.24M 36.66M
Net income applicable to common shares - - - -14.24M 36.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 24.74M 64.00M 103.65M 123.09M 160.03M
Intangible assets 7.22M 26.10M 26.40M 26.77M 27.20M
Other current assets 0.63M 1.34M 1.60M 0.76M 2.34M
Total liab 4.11M 9.69M 17.63M 8.57M 25.56M
Total stockholder equity 20.63M 54.31M 86.01M 114.52M 134.48M
Deferred long term liab - - - 2.42M 7.23M
Other current liab 0.98M 3.11M 3.06M 2.62M 5.77M
Common stock 0.07M 0.04M 0.04M 0.03M 0.03M
Capital stock 0.07M 0.04M 0.04M 0.03M 0.03M
Retained earnings -80.37M -33.04M 4.60M 39.93M 54.17M
Other liab - - - 4.64M 12.96M
Good will - - - 0.00M 14.71M
Other assets - - 0.00M - 0.07M
Cash 11.88M 2.94M 14.92M 22.97M 88.61M
Total current liabilities 3.54M 7.32M 5.75M 3.87M 12.60M
Current deferred revenue 0.01M 0.04M 0.36M - 0.15M
Net debt -10.65M -0.78M -11.93M -22.63M -88.61M
Short term debt 0.66M 0.92M 0.84M 0.30M 6.07M
Short long term debt total 1.24M 2.15M 2.99M 0.35M -
Other stockholder equity 100.93M 86.90M 81.23M 74.26M 80.27M
Property plant equipment - - - 2.54M 1.93M
Total current assets 13.69M 32.29M 62.14M 92.73M 115.12M
Long term investments 0.35M 0.73M 0.77M 0.67M 0.07M
Net tangible assets - - - 87.75M 92.57M
Short term investments 0.00M 26.81M 43.63M 58.29M 1.26M
Net receivables 0.19M 0.13M 0.33M 5.40M 20.91M
Inventory 0.99M 1.07M 1.66M 5.31M 2.00M
Accounts payable 1.88M 3.29M 1.48M 0.95M 0.61M
Accumulated other comprehensive income - 0.42M 0.15M 0.29M -
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - 39.93M 54.17M
Treasury stock - - - -14.21M -
Non currrent assets other 0.35M 0.00M -0.00M 0.67M 0.07M
Non current assets total 11.05M 31.71M 41.51M 30.35M 44.91M
Capital lease obligations 1.24M 2.15M 2.99M 0.35M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 27.08M 17.07M -47.53M -56.74M 3.57M
Change to liabilities - - - -4.69M -0.46M
Total cashflows from investing activities 26.27M 17.07M 15.39M -58.17M 4.10M
Total cash from financing activities 11.81M 0.10M -1.36M -14.03M 0.45M
Change to operating activities - - - -0.22M -2.05M
Net income -46.90M -37.64M -35.33M -14.24M 36.66M
Change in cash 8.95M -11.98M -8.06M -65.63M 45.63M
Begin period cash flow 2.94M 14.92M 22.97M 88.61M 42.98M
End period cash flow 11.88M 2.94M 14.92M 22.97M 88.61M
Total cash from operating activities -29.14M -29.16M -22.08M 6.57M 41.08M
Issuance of capital stock 11.80M 0.10M 0.00M - 0.00M
Depreciation 1.11M 1.38M 1.23M 1.28M 0.34M
Other cashflows from investing activities -0.10M -0.14M - - 1.69M
Change to inventory 0.13M 0.27M 0.41M -3.53M 5.71M
Change to account receivables -0.03M 0.19M 2.54M 14.96M -8.74M
Sale purchase of stock - 0.00M -1.36M -14.21M 0.45M
Other cashflows from financing activities 6.97M 0.10M 15.39M -0.30M -24.71M
Change to netincome - - - 21.02M 6.98M
Capital expenditures 0.70M 0.75M 1.37M 1.43M 0.67M
Change receivables - - - 14.96M -8.74M
Cash flows other operating - - - -8.24M -2.20M
Cash and cash equivalents changes - - - -65.63M 45.63M
Change in working capital -3.17M 2.75M 5.64M 6.37M -2.90M
Stock based compensation 2.25M 5.43M 8.34M 7.54M 5.51M
Other non cash items 17.57M -1.08M 0.46M 10.42M 0.54M
Free cash flow -29.84M -29.90M -23.45M 5.14M 40.41M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CODX
Co-Diagnostics, Inc. Common Stock		 0.01
5.49%		 0.27 - 15.36 11.03 0.63 8.47 0.52
ABT
Abbott Laboratories		 -0.36
0.33%		 109.56 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.14
0.14%		 101.66 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -0.84
0.26%		 325.03 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Co-Diagnostics, Inc. Common Stock

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

2401 S. Foothill Drive, Salt Lake City, UT, United States, 84109

801 438 1036

https://co-dx.com

115

Name Title Year Born
Mr. Dwight H. Egan Chairman, CEO & Pres 1953
Mr. Brian L. Brown CPA CFO & Company Sec. 1976
Mr. Reed L. Benson Gen. Counsel 1948
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board 1977
Mr. Dan Bohrer CPA VP of Fin. & Accounting NA
Dr. Mark Poritz Ph.D. Chief Scientific Officer NA
Mr. Andrew Benson Head of Investor Relations NA
Dr. Mayuranki Almaula Sr. VP of Overseas Operations & Strategic Alliances NA
Mr. Cameron Gundry Head of Commercialization LATAM/EUR NA
Mr. David Nielsen Chief Operating Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…